Abstract
Secretory vesicles in endocrine cells store hormones such as growth hormone (GH) and insulin before their release into the bloodstream. The molecular mechanisms governing budding of immature secretory vesicles from the trans-Golgi network (TGN) and their subsequent maturation remain unclear. Here, we identify the lipid binding BAR (Bin/amphiphysin/Rvs) domain protein PICK1 (protein interacting with C kinase 1) as a key component early in the biogenesis of secretory vesicles in GH-producing cells. Both PICK1-deficient Drosophila and mice displayed somatic growth retardation. Growth retardation was rescued in flies by reintroducing PICK1 in neurosecretory cells producing somatotropic peptides. PICK1-deficient mice were characterized by decreased body weight and length, increased fat accumulation, impaired GH secretion, and decreased storage of GH in the pituitary. Decreased GH storage was supported by electron microscopy showing prominent reduction in secretory vesicle number. Evidence was also obtained for impaired insulin secretion associated with decreased glucose tolerance. PICK1 localized in cells to immature secretory vesicles, and the PICK1 BAR domain was shown by live imaging to associate with vesicles budding from the TGN and to possess membrane-sculpting properties in vitro. In mouse pituitary, PICK1 co-localized with the BAR domain protein ICA69, and PICK1 deficiency abolished ICA69 protein expression. In the Drosophila brain, PICK1 and ICA69 co-immunoprecipitated and showed mutually dependent expression. Finally, both in a Drosophila model of type 2 diabetes and in high-fat-diet-induced obese mice, we observed up-regulation of PICK1 mRNA expression. Our findings suggest that PICK1, together with ICA69, is critical during budding of immature secretory vesicles from the TGN and thus for vesicular storage of GH and possibly other hormones. The data link two BAR domain proteins to membrane remodeling processes in the secretory pathway of peptidergic endocrine cells and support an important role of PICK1/ICA69 in maintenance of metabolic homeostasis.
Introduction: The Challenge of Hormone Packaging
Endocrine cells function as biological factories, synthesizing vital hormones like insulin and growth hormone (GH). These hormones must be packaged into specialized containers known as dense-core secretory vesicles (DCVs) at the trans-Golgi network (TGN) before being released into the bloodstream. While the "budding" process of these vesicles is a known cellular phenomenon, the specific molecular machinery responsible for bending the cell membrane to create these packages has remained elusive.
This study investigates the role of PICK1 (protein interacting with C kinase 1), a protein containing a membrane-curving "BAR domain," as a potential "molecular sculptor" in this packaging process.
Methods: A Multi-Organism Genetic Approach
The researchers employed a comprehensive multi-organism strategy to investigate PICK1 function:
- Genetic Models: They generated PICK1-null strains of both Drosophila melanogaster (fruit flies) and mice to observe systemic physiological changes.
- Rescue Experiments: In Drosophila, PICK1 was reintroduced specifically into neurosecretory cells to determine if growth deficits could be reversed.
- Imaging and Biochemistry: Confocal and electron microscopy (EM) visualized vesicle numbers and protein localization. Live-cell imaging tracked vesicle budding in real-time, while in vitro assays tested the ability of purified PICK1 BAR domains to physically tubulate artificial lipid membranes.
- Metabolic Phenotyping: The team performed oral glucose tolerance tests (OGTT), insulin tolerance tests (ITT), and measured hormone levels (GH, IGF-1) in the blood and pituitary.
Key Insights: The PICK1-ICA69 Partnership
A central discovery of this work is that PICK1 does not operate in isolation. It forms a heterodimer with another BAR-domain protein, ICA69. These two proteins mutually stabilize each other; in PICK1-deficient mice, the ICA69 protein is almost entirely lost, despite its mRNA remaining present.
Furthermore, the study demonstrates that the PICK1 BAR domain is an active participant in membrane remodeling. In vitro tests confirmed its ability to shape membranes into tubes, suggesting it provides the physical force necessary to "pinch off" new vesicles from the Golgi. This fundamental mechanism appears highly conserved, as the loss of PICK1 leads to similar phenotypes—stunted growth and decreased glucose tolerance—across species.
Key Results: Stunted Growth and Metabolic Dysfunction
The physiological impact of PICK1 deficiency is profound and consistent across models.
- Growth Retardation: PICK1-null mice exhibited significantly reduced body weight and length. In Drosophila, weight loss was significant but fully rescuable by re-expressing PICK1 in peptidergic neurons.
- Vesicle Depletion: Electron microscopy of the mouse pituitary showed a dramatic reduction in the number of secretory vesicles in GH-producing cells.
- Hormonal and Metabolic Deficits: PICK1-deficient mice showed lower GH storage in the pituitary and reduced circulating IGF-1. They also exhibited impaired insulin secretion and glucose intolerance. Interestingly, while GH replacement therapy corrected growth and fat accumulation, it did not resolve the glucose intolerance, indicating that PICK1 is independently required for both GH and insulin pathways.
- Metabolic Compensation: In models of obesity and diabetes, PICK1 mRNA levels were upregulated, suggesting the body attempts to increase its packaging machinery capacity under metabolic stress.
Discussion and Future Directions
While the link between PICK1 and the biogenesis of GH and insulin vesicles is clear, its role in other hormonal pathways remains to be fully elucidated. The exact mechanism of "fission"—the final release of the vesicle—likely involves additional proteins like dynamin.
The findings have significant clinical implications, as the mouse phenotype closely mirrors human idiopathic growth hormone deficiency. Future research may reveal whether mutations in PICK1 or ICA69 underlie unexplained growth or metabolic disorders in human patients.
Summary updated